Suchergebnisse - "Janku, Filip"

PubPharm (44)

1

Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies

enthalten in: Cancer immunology research | 2022

von Janku, F. | Han, S. | Doi, T. | +15

2

First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2022

von Janku, F. | Beom, S. | Moon, Y. | +14

3

First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer

enthalten in: Investigational new drugs | 2021

von Janku, F. | LoRusso, P. | Mansfield, A. | +6

4

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Wick, A. | Bähr, O. | Schuler, M. | +28

5

Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Mellinghoff, I. | Ellingson, B. | Touat, M. | +18

6

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma : a phase 1 study

enthalten in: The lancet. Gastroenterology & hepatology | 2019

von Lowery, M. | Burris, H. | Janku, F. | +19

CommentIn: Lancet Gastroenterol Hepatol. 2019 Sep;4(9):661-662. - PMID 31300361

7

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

enthalten in: Cancer cell | 2019

von Smith, B. | Kaufman, M. | Lu, W. | +26

CommentIn: Nat Rev Cancer. 2019 Jul;19(7):370. - PMID 31201392

8

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer

enthalten in: Investigational new drugs | 2018

von Kato, S. | Jardim, D. | Johnson, F. | +16

9

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer

enthalten in: Oncotarget | 2017

von Wang, Z. | Piha-Paul, S. | Janku, F. | +14

10

Circulating tumor DNA-From bench to bedside

enthalten in: Current problems in cancer | 2017

von Lim, J. | Janku, F. | Yap, T.

1
2
3
4
5
Nächster »
[5]